Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical observations without systematic review methodology.
PubMed 41034339 · doi:10.1038/s41584-025-01302-0
What was done
Narrative review evaluating the mechanistic and clinical literature on glucagon-like peptide-1 receptor agonists (GLP-1RAs) in comorbid obesity or type 2 diabetes and various arthritides, including knee osteoarthritis, gout, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.
What was found
The abstract reports no numerical data. It notes that preclinical in vitro and in vivo studies indicate weight-loss-independent chondroprotective and anti-inflammatory mechanisms. Clinically, available data suggest GLP-1RAs improve knee osteoarthritis pain and function while lowering surgical intervention risk. However, they do not appear to directly prevent acute gout attacks, and evidence remains incomplete regarding their impact on osteoarthritis incidence or inflammatory arthritis disease activity and progression.
Why it matters
Highlights the expanding potential of GLP-1RAs beyond metabolic and cardiovascular management to joint-specific outcomes in rheumatology.
Limits
As a narrative review, the abstract lacks quantitative pooled estimates, sample sizes, or detailed evaluation of underlying study risk of bias. Clinical evidence in inflammatory arthritides (rheumatoid arthritis, psoriatic arthritis, spondyloarthritis) is currently unestablished.
Cited by
- supports GLP-1 receptor agonists have anti-inflammatory effects on joints and the brain.